HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study.

Abstract
Coenzyme Q10 (CoQ10) provides the energy for vital cellular functions and is known to act as an antioxidant. We conducted an open label study to examine the clinical effects of supplementation of the reduced form of CoQ10, ubiquinol, in addition to conventional glucose-lowering agents in patients with type 2 diabetes. Nine subjects (3 males and 6 females) with type 2 diabetes and receiving conventional medication were recruited. The subjects were assigned to receive an oral dose of 200 mg ubiquinol daily for 12 weeks. The effect of ubiquinol on blood pressure, lipid profile, glycemic control, oxidative stress, and inflammation were examined before and after ubiquinol supplementation. In addition, five healthy volunteers were also assigned to receive an oral dose of 200 mg ubiquinol daily for 4 weeks to examine the effects of ubiquinol on insulin secretion. In patients with diabetes, there were no differences with respect to blood pressure, lipid profile, oxidative stress marker, and inflammatory markers. However, there were significant improvements in glycosylated hemoglobin (53.0 ± 4.3 to 50.5 ± 3.7 mmol/mol, P = 0.01) (7.1 ± 0.4 to 6.8 ± 0.4%, P = 0.03). In healthy volunteers, the insulinogenic index (0.65 ± 0.29 to 1.23 ± 0.56, P = 0.02) and the ratio of proinsulin to insulin were significantly improved (3.4 ± 1.8 to 2.1 ± 0.6, P = 0.03). The results of our study are consistent with the suggestion that the supplementation of ubiquinol in subjects with type 2 diabetes, in addition to conventional antihyperglycemic medications, improves glycemic control by improving insulin secretion without any adverse effects
AuthorsMorito Mezawa, Minoru Takemoto, Shunichiro Onishi, Ryoichi Ishibashi, Takahiro Ishikawa, Masaya Yamaga, Masaki Fujimoto, Emiko Okabe, Peng He, Kazuki Kobayashi, Koutaro Yokote
JournalBioFactors (Oxford, England) (Biofactors) 2012 Nov-Dec Vol. 38 Issue 6 Pg. 416-21 ISSN: 1872-8081 [Electronic] Netherlands
PMID22887051 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 International Union of Biochemistry and Molecular Biology, Inc.
Chemical References
  • Antioxidants
  • Blood Glucose
  • Hypoglycemic Agents
  • Lipids
  • Ubiquinone
  • ubiquinol
Topics
  • Aged
  • Antioxidants (pharmacology, therapeutic use)
  • Blood Glucose (metabolism)
  • Diabetes Mellitus, Type 2 (blood, drug therapy)
  • Female
  • Humans
  • Hypoglycemic Agents (pharmacology, therapeutic use)
  • Lipids (blood)
  • Male
  • Middle Aged
  • Pilot Projects
  • Ubiquinone (analogs & derivatives, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: